About Chrono Therapeutics Inc.
The Pioneer of Individually - Optimized Transdermal Drug Products
Chrono Therapeutics Inc. (CTI) is a specialty pharmaceutical company focused on the development, manufacture and commercialization of drug-products utilizing our proprietary formulations and transdermal drug delivery platform-ChronoDose™.
CTI’s experienced management team and world-leading class partners merge micro-engineering, pharmacokinetics, formulation, manufacturing and patent expertise to offer patients highly effective, convenient and user-friendly drugs products.
Our initial drug product has been validated through in vivo human clinical studies conducted at the University of Basel and the Basel Hospital. Several of our secondary drug products have been validated in vitro at the University of Basel’s PharmaCenter and CTI’s own in-house laboratories.
This "storehouse" of ChronoDose™ solutions to be made available to the public and the pharmaceutical industry in the near-term represents vast development potential. We believe that ChronoDose™ will improve the lives of young, middle aged and elderly patients across many therapeutic areas.
Recent Developments
July 3, 2008
Chrono Therapeutics consummates investment banking agreement with leading boutique firm
June 23, 2008
Chrono Therapeutics adds Bret Berner, Ph.D. as its Chief Science Officer.
April 12, 2008
Chrono Therapeutics adds Dr. Lawrence Blob, MD as its Chief Medical Officer.
March 22, 2008
Chrono Therapeutics receives favorable preliminary information from the Food and Drug Administration (FDA).
March 11, 2008
Favorable Scientific Review from industry leaders of Chrono Therapeutics Human Clinical Trial Report issued from University of Basel Hospital.
February 10, 2008
Dr. Howard Maibach joins Chrono Therapeutics to lead the Advisory Board.